Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06640166 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.

Study acronym: ECLYPse
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 12, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Site details revised at 1 of 3 sitesv2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this study is to determine the activity of encorafenib plus cetuximab in combination with FOLFIRI in patients with BRAF V600E mutated metastatic colorectal cancer progressing on encorafenib plus cetuximab administered in second line.
Trial Details
NCT Number NCT06640166
Lead Sponsor Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Collaborators: Pierre Fabre Pharma GmbH
Conditions
(from sponsor)		 Colorectal Carcinoma, Colorectal Neoplasms, Colorectal Tumor, Colorectal Adenocarcinoma, Colorectal Cancer (CRC), Colorectal Cancer, Colon Cancer, Colon Adenocarcinoma +2 more
Related terms Colonic Neoplasms, Colorectal Neoplasms
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov